|Company name||Boston Scientific Corporation|
|Class period||February 26, 2015 – April 16, 2019|
|Court||Southern District of New York|
NEW YORK, April 24, 2019 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Boston Scientific Corporation (NYSE: BSX) securities between February 26, 2015 and April 16, 2019 (the “Class Period”). Investors have until June 24, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The complaint alleges that during the Class Period defendants made materially false and misleading statements regarding the company’s business, operational and compliance policies. Specifically, the complaint alleges that defendants made false and/or misleading statements and/or failed to disclose that: (1) Boston Scientific’s surgical mesh products indicated for the transvaginal repair of POP were unsafe; (2) accordingly, Boston Scientific’s continued marketing and sales of these devices in the United States was unlikely to be sustainable; (3) separately, the company had sold vaginal mesh implants containing counterfeit or adulterated resin products imported from China; (4) the foregoing conduct subjected the company to a heightened risk of regulatory scrutiny and/or government investigations; and (5) as a result, the company’s public statements were materially false and misleading at all relevant times.
If you purchased Boston Scientific securities during the Class Period or continue to hold shares purchased before the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at email@example.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.